# Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)

> **NCT04402515** · — · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** TIO/OLO
- **DRUG:** ICS

## Key facts

- **NCT ID:** NCT04402515
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-28
- **Primary completion:** 2022-01-15
- **Final completion:** 2022-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** not due to safety reasons
- **Last updated:** 2021-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402515, "Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04402515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*